These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Retinoic acid selectively inhibits the vascular permeabilizing effect of VPF/VEGF, an early step in the angiogenic cascade. Pal S; Iruela-Arispe ML; Harvey VS; Zeng H; Nagy JA; Dvorak HF; Mukhopadhyay D Microvasc Res; 2000 Sep; 60(2):112-20. PubMed ID: 10964585 [TBL] [Abstract][Full Text] [Related]
28. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Watanabe Y; Lee SW; Detmar M; Ajioka I; Dvorak HF Oncogene; 1997 May; 14(17):2025-32. PubMed ID: 9160882 [TBL] [Abstract][Full Text] [Related]
29. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. Walter DH; Hink U; Asahara T; Van Belle E; Horowitz J; Tsurumi Y; Vandlen R; Heinsohn H; Keyt B; Ferrara N; Symes JF; Isner JM Lab Invest; 1996 Feb; 74(2):546-56. PubMed ID: 8780172 [TBL] [Abstract][Full Text] [Related]
30. Decreased release of IL-10 by monocytes from patients with lipoid nephrosis. Matsumoto K Clin Exp Immunol; 1995 Dec; 102(3):603-7. PubMed ID: 8536379 [TBL] [Abstract][Full Text] [Related]
31. Interleukin-1alpha promotes angiogenesis in vivo via VEGFR-2 pathway by inducing inflammatory cell VEGF synthesis and secretion. Salven P; Hattori K; Heissig B; Rafii S FASEB J; 2002 Sep; 16(11):1471-3. PubMed ID: 12205052 [TBL] [Abstract][Full Text] [Related]
32. Characterization of the increase in vascular permeability induced by vascular permeability factor in vivo. Collins PD; Connolly DT; Williams TJ Br J Pharmacol; 1993 May; 109(1):195-9. PubMed ID: 7684302 [TBL] [Abstract][Full Text] [Related]
33. IL-18 initiates release of matrix metalloproteinase-9 from peripheral blood mononuclear cells without affecting tissue inhibitor of matrix metalloproteinases-1: suppression by TNF alpha blockage and modulation by IL-10. Nold M; Goede A; Eberhardt W; Pfeilschifter J; Mühl H Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):68-75. PubMed ID: 12616343 [TBL] [Abstract][Full Text] [Related]
34. Studies of a glomerular permeability factor in patients with minimal-change nephrotic syndrome. Yoshizawa N; Kusumi Y; Matsumoto K; Oshima S; Takeuchi A; Kawamura O; Kubota T; Kondo S; Niwa H Nephron; 1989; 51(3):370-6. PubMed ID: 2918948 [TBL] [Abstract][Full Text] [Related]
35. Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells. Lee JD; Swisher SG; Minehart EH; McBride WH; Economou JS J Leukoc Biol; 1990 May; 47(5):475-9. PubMed ID: 2335755 [TBL] [Abstract][Full Text] [Related]
36. Mechanisms of proteinuria: vascular permeability factor in congenital nephrotic syndrome of the Finnish type. Haltia A; Solin ML; Jalanko H; Holmberg C; Miettinen A; Holthöfer H Pediatr Res; 1996 Nov; 40(5):652-7. PubMed ID: 8910928 [TBL] [Abstract][Full Text] [Related]
37. The contribution of interleukin (IL)-4 and IL-13 to the epithelial-mesenchymal trophic unit in asthma. Richter A; Puddicombe SM; Lordan JL; Bucchieri F; Wilson SJ; Djukanovic R; Dent G; Holgate ST; Davies DE Am J Respir Cell Mol Biol; 2001 Sep; 25(3):385-91. PubMed ID: 11588018 [TBL] [Abstract][Full Text] [Related]